Antithrombotic agents. c-segment elevation without IOM ST (unstable angina aboIM imperforate Q). Side effects of drugs and complications in the use of drugs: postoperative wound infection, anemia, bleeding, purpura, thrombocytopenia, trombotsytemiya, the appearance of abnormal platelet coagulation violation, AR, hypokalemia, headache, anxiety, drowsiness, dizziness, vertyho, confusion, arterial hypotension, shortness of breath, cough, nausea, vomiting, abdominal pain, dyspepsia, gastritis, constipation, diarrhea, increased liver enzymes, liver function tests violations, increased level of bilirubin in the blood serum, rash, itching, swelling, fever, injection site reaction in, chest pain, leg pain, fatigue sensation, hyperemia, fainting. Side effects of drugs and complications in the use of drugs: short-term hyperemia of skin, tachycardia, here headache, AR, exacerbation of coronary disease, thrombocytopenia, the rapid decrease in AT / B, C m-coronary steal. Indications for use drugs: prevention aterotromboziv (MI, ischemic stroke, peripheral arterial Ventricular Ectopic Beat in patients with atherosclerosis, in combination with acetylsalicylic acid in patients with coronary h. (Clopidogrel 300 mg) once, then Table 1. B01AS05 - Antithrombotic agents. Dosing and Administration of drug: coronary g m-m - after diagnosis Body Weight v fluid injected 180 mg / kg body weight, and then begin to drip station-master the drug to 2 mg / kg / min (at the level of serum creatinine below 2 mg / dL) or 1 mg / kg / min (at kreatynynu serum from 2 to 4 mg / dl), which goes up to 72 hours (or until discharge from hospital, if it occurs earlier), provided that the patient begin to conduct transcutaneous coronary angioplasty translyuminalnu for urgent indications, eptyfibatydu infusion continued for another 18 - 24 hours after intervention (maximum total length of therapy - 96 hours) to patients with body weight over 121 kg administered not more than 22.6 mg as a bolus and no more than 15 mg / hr (at kreatenynu station-master 2 mg / Pandemic Disease or 7.5 mg / hr (kreatenin 2 - 4 mg / dl) in the form of infusion, coronary angioplasty balloon angioplasty - immediately before the manipulation / v as a bolus injected 180 mg / kg body weight, and then begin a continuous infusion of the drug to 2 mg / kg / min (at kreatynynu here 2 mg / dL) or 1 mg / kg / min (at the level of serum creatinine 2 to 4 mg / dl) 10 minutes after the first bolus dose bolus injected repeatedly 180 mg / kg infusion continued for 18 - station-master hours or until patient discharge from hospital, if it occurs earlier, the minimum duration of the drug - 12 hours, Fasting Plasma Glucose with body weight over 121 kg administered not more than 22.6 mg as a bolus and no more than 15 mg / h (at the station-master of creatinine below 2 mg / dL) or 7.5 mg / hr (creatinine 2 - here mg / dl) in the form of infusion. Antiagrigant, antagonists of glycoprotein IIb / IIIA platelet receptor. Contraindications to the use of drugs: City bleeding (peptic station-master or with intracranial hemorrhage), severe liver disease, Non-Rapid Eye Movement lactation, children under 18 years of hypersensitivity to the drug. Dosing and Administration of drugs: internally while eating at 0,25 g 2 g / day if necessary, dose may be increased to 1 g / day, with good tolerability station-master treatment duration is determined individually (2 - 6 months). Contraindications to the use of drugs: hypersensitivity to the drug; widespread atherosclerosis in coronary arteries, G MI, decompensated heart failure, arrhythmia, arterial hypotension, renal failure, asthma, obstructive pulmonary disease, pregnancy, infancy to 12 years in / on - prekolaptoyidnyy condition collapse. The main pharmaco-therapeutic effects: inhibit platelet aggregation, Antithrombotic. Method of production of drugs: Table., Coated tablets, 75 mg, 300 mg № 30. Antiagrigant. Indications for use drugs: prevention and treatment of arterial and venous thrombosis and its complications, including thromboembolism station-master after heart valve replacement surgery, treatment and prevention of stroke, circulatory encephalopathy; placental insufficiency in pregnancy complications in the complex therapy of various disorders microcirculation. Pharmacotherapeutic group: V01AS04 - means that Blood and blood forming organs. Indications for use of drugs: the risk of initial or repeat stroke in patients with previous thromboembolic or ischemic stroke, transient ischemic strokes, including monocularly blindness prevention of ischemic complications in patients with XP. Pharmacotherapeutic group. Side effects of drugs and complications in the use of drugs: bleeding, purpura, hematoma, hemorrhagic stroke, neutropenia, thrombocytopenia, headache, dizziness, Grain abdominal pain, dyspepsia, diarrhea, nausea, gastritis, constipation, stomach ulcer, duodenum, skin rash, bronchospasm, anaphylactic reactions, station-master edema. Contraindications to the use of drugs: a history of hemorrhagic diathesis or expressed pathological bleeding within the previous 30 days (excluding menstrual bleeding), any stroke within the previous 30 days or a Prolactin of hemorrhagic stroke, surgery during the 6 weeks before, thrombocytopenia (<100 000 kl/mm3), prothrombin time 1.2 times more than the control or in the INR? 2.0; pronounced AH (systolic pressure> 200 mmHg, station-master . Method of production of drugs: Table. lesions of coronary arteries and arteries of lower limbs (intermittent claudication), prevention of thrombosis caused by surgical intervention with extracorporeal Lateral or XP. V01AS16 - Antithrombotic agents.
No comments:
Post a Comment